Table 3.

Antiviral antibodies and other variables in relation to severity of PDB

	Mild PDB (n = 152)	Moderate PDB (n = 163)	Severe PDB (n = 145)	p-value
Age (years)	74.7 ± 6.2	71.2 ± 8.6	71.5 ± 8.6	<0.0001
Male gender	85 (55.9%)	78 (47.8%)	76 (52.4%)	0.35
Measles virus (IU/ml)	4.5 ± 18.6	1.9 ± 6.0	2.4 ± 8.9	0.13
Respiratory syncytial virus (IU/ml)	224.5 ± 147.9	228.8 ± 144.7	227.5 ± 141.6	0.96
Canine distemper virus (IU/ml)	2.40 ± 1.11	2.42 ± 1.11	2.24 ± 1.01	0.30
Mumps virus (UI/ml)	2.96 ± 0.91	3.05 ± 0.82	3.0 ± 0.81	0.60
Varicella zoster virus (IU/ml)	0.86 ± 0.76	0.88 ± 0.66	0.88 ± 0.77	0.95
Rubella virus (IU/ml)	28.6 ± 11.6	30.0 ± 12.0	28.9 ± 10.7	0.38
SQSTM1 mutation	3 (2.0%)	16 (9.8%)	20 (13.8%)	0.001
SF36 bodily pain	40.2 ± 10.9	38.6 ± 10.7	38.0 ± 10.5	0.19
SF36 physical functioning	38.1 ± 11.0	36.2 ± 11.5	34.3 ± 10.4	0.02
SF36 mental functioning	47.9 ± 11.0	49.6 ± 11.3	47.7 ± 11.8	0.31

Patients with mild PDB had a disease severity score of 3 or less, those with moderate a score of 4–6 and those with severe PDB a score of 7 or more. Values are mean ± standard deviation or numbers (%). The p-values refer to differences across groups, as assessed by ANOVA